Health Care Equipment

Allgens

Allgens released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 48.68 M, actual EPS CNY 0.01

Allgens to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Allgens to Release FY2025 Earnings Report on April 29, 2026 Pre-Market BJT

Allgens released FY2025 Annual Earnings on February 27 Pre-Market (BJT), actual revenue CNY 223.74 M, actual EPS CNY 0.1

Allgens released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 67.68 M, actual EPS CNY -0.0007

Allgens released FY2025 Q3 earnings on October 29 During-Market BJT, actual revenue CNY 56.02 M, actual EPS CNY 0.0391

Allgens released FY2025 9 Months Earnings on October 29 During-Market BJT, Actual Revenue: CNY 156.06 M, Actual EPS: CNY 0.092

Allgens to Release FY2025 Q3 Earnings Report on October 30 During-Market BJT

Allgens released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 100.04 M, actual EPS CNY 0.06

Allgens released FY2025 Q2 earnings on August 29 After-Market BJT, actual revenue CNY 57.58 M, actual EPS CNY 0.0428

Allgens to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Aojing Medical Obtains Medical Device Production License

Osteo Biotech's Artificial Bone Repair Material Approved by Vietnam's Health Ministry

Founder of Bonioral Medical, Cui Fuzhai, Passed Away

BioVeda China RMB Investment Limited reduces holdings in AJ Medical

Allgens released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 42.46 M, actual EPS CNY 0.01

Allgens FY2025 Q1 Earnings Release on April 26 After-Market BJT

Allgens FY2024 Annual Earnings Release on April 26, 2025 (BJT)

Aojing Medical's Artificial Bone Repair Material Approved by the Vietnamese Ministry of Health

Allgens released FY2024 Annual Earnings on February 27, 2025 (BJT) with actual revenue of CNY 206.03 M and EPS of CNY -0.09

688613

According to the Zhitong Finance APP, Allgens announced that the company submitted the registration application materials for its absorbable composite bone repair material medical device products to the National Medical Products Administration in August 2024. The company recently received notification from the National Medical Products Administration that its absorbable composite bone repair material medical device products have been approved

Zhitong

Allgens: Absorbable composite bone repair material medical device product approved

According to the Zhitong Finance APP, Allgens announced that the company recently received a notice from Qilun Tianyou regarding the share reduction plan. Due to its own funding arrangements, Qilun Tianyou will reduce its holdings based on market conditions through centralized bidding and block trading. Qilun Tianyou plans to reduce its holdings in Allgens by no more than 1.3555 million shares, accounting for 1% of Allgens' total shares

Allgens: Qilun Tianyou plans to reduce its holdings by no more than 1% of shares

300502

36Kr learned that the three major A-share indices showed mixed results at the midday break, with the Shanghai Composite Index up 0.17%, the Shenzhen Component Index up 0.16%, and the ChiNext Index down 1.33%. The healthcare, shipping, and automotive parts sectors led the gains, with Allgens rising over 12%, Ningbo Yuantong and Shuanglin Co., Ltd. rising over 6%. The communication equipment, precious metals, and diversified financial sectors weakened, with Eoptolink falling over 12%, Western Gold falling over 5%, and PetroChina Capital falling over 2%

36Kr

Eoptolink

The three major A-share indices closed mixed at noon, with Eoptolink down over 12%

688277

300760

300633

002901

688114

The A-share medical device sector fluctuated and rose, with Allgens and United Imaging Healthcare increasing by over 10%. SONOSCAPE, MGI, Double Medical, Tinavi, and Mindray also followed suit

Tinavi

Mindray

SONOSCAPE

Double Medical

Allgens announced that its shareholder BioVeda plans to reduce its holdings in the company by no more than 1,355,515 shares, accounting for 1% of the company's total shares, through centralized bidding and block trading. The reduction period is from September 22, 2025, to December 22, 2025

Allgens: Shareholders plan to reduce their holdings by no more than 1% of the company's shares

Allgens announced that its OssaNova™ artificial bone repair material has obtained registration certification in Vietnam. This material is based on independently developed intellectual property for in vitro biomimetic mineralization technology and is suitable for bone defect repair in dentistry and orthopedic surgery. The product can be replaced by newly formed bone tissue while guiding bone regeneration, demonstrating good repair capabilities. The acquisition of this registration certification will promote the company's sales in overseas markets and marks an important progress in its overseas business expansion

Allgens: OssaNova™ artificial bone repair material has obtained registration certification in Vietnam

Allgens' wholly-owned subsidiary, Beijing Allgens Medical Devices Co., Ltd., recently obtained a medical device manufacturing license issued by the Beijing Municipal Medical Products Administration, with a production scope that includes Class III absorbable surgical dressings. This license provides qualification assurance for the production and market sales of the company's future products and is expected to have a positive impact on the company's operations

Allgens' subsidiary obtains medical device production license

According to the Zhitong Finance APP, Allgens announced that the company submitted the registration application materials for its artificial bone repair material products to the Ministry of Health of Vietnam in December 2024. The company recently received notification from the Ministry of Health of Vietnam that its artificial bone repair material products have been approved

Allgens: Artificial bone repair material products obtained registration certificate in Vietnam

According to the Zhitong Finance APP, Allgens announced that the company's board of directors is saddened to announce that the company has received notification from the family of Mr. Cui Fuzhai, one of the founders and actual controllers of the company, that Mr. Cui Fuzhai unfortunately passed away recently due to illness at the age of 80